KRYS logo

KRYSTAL BIOTECH INC

KRYSNASDAQ
🏆 #888 by market capUS Equity
$335.02▼ $2.31 (−0.69%)
After hours · at close
🔔
Track KRYS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.7%
7d▼ 4.5%
14d▼ 0.3%
30d▼ 4.7%
ytd▲ 35.4%
1y▲ 89.5%
🏦Market Cap
$9.88B
Small Cap
📈Revenue Growth (YoY)
+22.6%
Healthy
📊Gross Margin
94.6%
High
💵FCF Margin
58.5%
Strong
⚖️P/S Ratio
22.8x
Expensive
Otter Score
80
Good

Trading Snapshot

Day Range
$331.63 – $340.41
52-Week Range
$158.08 – $382.54
Volume
$1.70B
Avg Volume
$1.59B
Shares Outstanding
29.5M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$438M
Last Q Revenue
$104M
P/E Ratio
41.6
P/S Ratio
22.8x
EPS (TTM)
$7.98
Dividend Yield
—
Dilution (1yr)
+0.2%

Why Investors Own KRYS

  • ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 31% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KRYS logo

KRYSTAL BIOTECH INC

KRYS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$389M▲ +33.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
92.6%▼ −0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$161M▲ +145.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$189M▲ +58.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.0M▲ +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$487M▲ +$149M YoY
StockOtter · stockotter.space

About KRYSTAL BIOTECH INC

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$445.71
▲ +33.0% Upside
High Target$510.33
Low Target$414.72
Based on 15 analysts

Latest News & Updates

🚀
Barron’s·2h ago

KRYSTAL BIOTECH INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift KRYS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

KRYSTAL BIOTECH INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.